Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma
Research output: Contribution to journal › Editorial › Research › peer-review
Documents
- Fulltext
Final published version, 280 KB, PDF document
| Original language | English |
|---|---|
| Article number | 00306-2021 |
| Journal | ERJ Open Research |
| Volume | 7 |
| Issue number | 3 |
| Number of pages | 5 |
| ISSN | 2312-0541 |
| DOIs | |
| Publication status | Published - 2021 |
- QUALITY-OF-LIFE, ADD-ON THERAPY, ANTIIMMUNOGLOBULIN-E THERAPY, SEVERE ALLERGIC-ASTHMA, LONG-TERM CONTROL, DOUBLE-BLIND, ANTIBODY OMALIZUMAB, PERSISTENT ASTHMA, MODERATE, MULTICENTER
Research areas
ID: 301615049